DBV Technologies S.A. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
DBVT Nasdaq 2834 www.dbv-technologies.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for DBV Technologies S.A.

DBV Technologies Secures Agreement with FDA on Safety Exposure Data Required for BLA for Viaskin® Peanut Patch in 4–7-year-olds, Accelerating the Timeline for a BLA Filing Submission to 1H 2026, & Reports 2024 Unaudited Financial Results... - Mar 24th, 2025 6:30 am
DBV Technologies to Participate in Upcoming AAAAI/WAO Joint Congress - Feb 25th, 2025 9:01 pm
Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF - Jan 13th, 2025 9:05 pm
DBV Technologies Announces Positive 3-Year Results from EPITOPE Phase 3 Open-Label Extension Study - Jan 8th, 2025 9:05 pm
DBV Aligns With FDA On Accelerated Approval For Viaskin Peanut Patch In Younger Kids - Dec 12th, 2024 2:59 pm
DBV Confirms Alignment with U.S. FDA on Accelerated Approval Pathway for the Viaskin® Peanut Patch in Toddlers 1 – 3 Years-Old - Dec 11th, 2024 9:05 pm
Information regarding the total number of voting rights and  total number of shares of the Company as of November 30, 2024 - Dec 2nd, 2024 9:30 pm
DBV Technologies Announces Plan to Implement ADS Ratio Change - Nov 11th, 2024 9:30 pm
DBV Technologies’ stock slides as financial woes worsens - Nov 7th, 2024 5:07 pm
DBV Technologies Reports Third Quarter 2024 Financial Results - Nov 6th, 2024 9:30 pm
DBV Technologies price target raised to $7 from $5 at H.C. Wainwright - Oct 24th, 2024 12:31 pm
DBV Announces Positive Regulatory Updates for the Viaskin® Peanut Patch in the United States and Europe - Oct 22nd, 2024 8:45 pm
DBV Technologies to Participate in Upcoming ACAAI 2024 Congress - Oct 18th, 2024 8:30 pm
Information regarding the total number of voting rights and total number of shares of the Company as of September 30, 2024 - Oct 14th, 2024 8:30 pm
DBV Technologies Completes Screening for the VITESSE Phase 3 Clinical Trial - Sep 23rd, 2024 8:30 pm
DBV Technologies to Participate in the H.C. Wainwright 26th Annual Global Investment Conference - Sep 4th, 2024 8:30 pm
Information regarding the total number of voting rights and total number of shares of the Company as of July 31, 2024 - Aug 2nd, 2024 8:30 pm
DBV Technologies Announces Filing of 2024 Half-Year Report ― Conditions for Accessing or Consulting the Report - Jul 30th, 2024 9:30 pm
DBV Technologies Provides Updates on the Viaskin Peanut Program in Children and Toddlers and Reports Second Quarter and Half-Year 2024 Financial Results - Jul 30th, 2024 8:30 pm
DBV Technologies to Report Second Quarter 2024 Financial Results and Business Update on July 30, 2024 - Jul 29th, 2024 5:30 am